DNLI peer analysis
Denali Therapeutics (DNLI) against its competitors: price, today's move, 1-year return and market value side by side.
DNLI and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ALEC Alector | $2.15 | -2.94% | 41.12% | $246.76M |
| AMLX Amylyx Pharmaceuticals | $28.02 | -2.91% | 99.43% | – |
| BHVN Biohaven | $15.14 | -1.78% | -12.91% | $2.33B |
| CGTX Cognition Therapeutics | $0.70 | -5.57% | -57.68% | – |
| IONS Ionis Pharmaceuticals | $41.21 | -5.31% | -44.44% | $7.23B |
| NBIX Neurocrine Biosciences | $156.00 | 6.78% | 13.01% | $14.85B |
| NMRA Neumora Therapeutics | $0.37 | -5.43% | -87.47% | – |
| PMN ProMIS Neurosciences | $3.31 | -70.13% | -68.30% | – |
| PRAX Praxis Precision Medicines | $273.58 | -4.32% | 36.11% | – |
| RAPP Rapport Therapeutics | $25.10 | 0.20% | -6.62% | – |
| DNLI Denali Therapeutics | $18.86 | -0.40% | 15.17% | $3.03B |
- DNLI's peers: ALEC (Alector), AMLX (Amylyx Pharmaceuticals), BHVN (Biohaven), CGTX (Cognition Therapeutics), IONS (Ionis Pharmaceuticals), NBIX (Neurocrine Biosciences), NMRA (Neumora Therapeutics), PMN (ProMIS Neurosciences).
Updated 2026-11-03 00:04 UTC